Sanara MedTech Inc. (SMTI) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Sanara MedTech Inc. (NASDAQ: SMTI) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $32.83 (-0.26% 1D, market cap $302.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, SMTI ranks #232 in composite RQD confidence.
Within the Health Care sector (Industrial Specialties), SMTI carries a Roarable D+ (55/100 RQD), trailing P/E of 8.1x, gross margin of 92.7%, and ROIC of 16.3%. By comparison, ZJYL (JIN MEDICAL INTERNATIONAL LTD. (Class A)) holds a D- grade (36/100 RQD, P/E N/A, ROIC —, cap $294.2M) and INGN (Inogen Inc) posts a D- grade (36/100 RQD, P/E 8.5x, ROIC -27.0%, cap $192.7M). Among the 5-stock peer group, SMTI leads on earnings multiple (8.1x) while SMTI leads on capital efficiency (16.3% ROIC).
Per SMTI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000714256), Sanara MedTech Inc. generated $103.1M in revenue (+19.0% YoY), $37.6M in net income, and $2.2M in free cash flow against $72.9M in total assets and $46.0M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.25 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC Form 4 / 13F Thermometer: 70% Net Buy • Cannibal Buyback (-0.60% YoY Shares)
Macro rate sensitivity & RSI-14 (30.4) create a -11 pt regime headwind
Even with a 55/100 (D+) score, SMTI faces multiple-compression risk if 8.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
Dilution & Margin Drag: Cannibal Buyback (-0.60% YoY Shares) — any gross margin slip below 90.2% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($34.48) or 200D SMA ($25.53) invalidates the momentum regime and cuts Target Base ($32.39) toward Bear Floor ($25.26).
Sanara MedTech Inc. (SMTI) slipped -0.26% to $32.83, trading at 86% of its 52-week range ($16.05 – $35.52). Stretched risk/reward at 8x P/E (16% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Sanara MedTech Inc. (SMTI) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Sanara MedTech Inc. (SMTI) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Sanara MedTech Inc. (SMTI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Sanara MedTech Inc. (SMTI) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Sanara MedTech Inc. (SMTI) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Sanara MedTech Inc. (SMTI) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Sanara MedTech Inc. (SMTI) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Sanara MedTech Inc. (SMTI) market action, institutional positioning, and fundamental catalysts.
https://www.sec.gov/ix?doc=/Archives/edgar/data/714256/000149315226049275/form8-k.htm
MiMedx Group (NASDAQ:MDXG) reported third-quarter net sales of $62 million, down 45% from a year earlier, as continued disruption in the wound care market offset growth in its surgical business. The company said surgical
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +19.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SMTI today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SMTI. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Sanara MedTech Inc. (SMTI) ranks #232 by composite RQD confidence (55/100, grade D+) and #518 by equity capitalization ($302.4M). Within this direct 5-issuer industry benchmark cohort, SMTI leads on earnings valuation at 8.1x trailing P/E, while SMTI leads on capital efficiency and profitability with 16.3% ROIC and 92.7% gross margin. SMTI currently leads its immediate peer cohort in composite quantitative strength at 55/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SMTI
ACTIVE
Sanara MedTech Inc. | D+ | 55/100 | 8.1x | 92.7% | 16.3% | -0.26% | $302.4M | Benchmark Subject |
| ZJYL JIN MEDICAL INTERNATIONAL LTD. (Class A) | D- | 36/100 | — | 29.2% | — | +26.34% | $294.2M | /zjyl-vs-smti → |
| INGN Inogen Inc | D- | 36/100 | 8.5x | 52.2% | -27.0% | -5.51% | $192.7M | /ingn-vs-smti → |
| AVR Anteris Technologies Global Corp. | E | 23/100 | — | 70.3% | -35.0% | -1.71% | $625.9M | /avr-vs-smti → |
| AGPU Axe Compute Inc. | D | 44/100 | — | — | -35.0% | -8.78% | $101.7M | /agpu-vs-smti → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sanara MedTech Inc. (SMTI) reported GAAP revenue of $103.1M (+19.0% vs. FY2024 revenue of $86.7M , and +58.7% cumulative change since FY2023) , GAAP net income of $37.6M, operating cash flow of $6.8M, and free cash flow of $2.2M (+1041.1% YoY). On the balance sheet, SMTI closed FY2025 with $72.9M in total assets against $46.0M in total debt (Altman Z-Score: 3.25, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $103.1M | $37.6M | $6.8M | $2.2M | $72.9M | $46.0M |
| FY2024 (FY) | 2024-12-31 | $86.7M | $9.7M | -$23.8K | -$229.6K | $88.1M | $30.7M |
| FY2023 (FY) | 2023-12-31 | $65.0M | $4.3M | -$3.2M | -$3.2M | — | — |
As of 2026-11-02, Sanara MedTech Inc. (NASDAQ: SMTI) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $32.83 (-0.26% 1D, market cap $302.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, SMTI ranks #232 in composite RQD confidence.
Within the Health Care sector (Industrial Specialties), SMTI carries a Roarable D+ (55/100 RQD), trailing P/E of 8.1x, gross margin of 92.7%, and ROIC of 16.3%. By comparison, ZJYL (JIN MEDICAL INTERNATIONAL LTD. (Class A)) holds a D- grade (36/100 RQD, P/E N/A, ROIC —, cap $294.2M) and INGN (Inogen Inc) posts a D- grade (36/100 RQD, P/E 8.5x, ROIC -27.0%, cap $192.7M). Among the 5-stock peer group, SMTI leads on earnings multiple (8.1x) while SMTI leads on capital efficiency (16.3% ROIC).
Per SMTI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000714256), Sanara MedTech Inc. generated $103.1M in revenue (+19.0% YoY), $37.6M in net income, and $2.2M in free cash flow against $72.9M in total assets and $46.0M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
SMTI last traded at $32.83 (-0.26% on volume of 97,205 shares), positioning the stock -4.79% below its 50-day simple moving average ($34.48) and +28.59% above its 200-day simple moving average ($25.53). Across its 52-week range of $16.05 to $35.52, SMTI sits at the 86.2% percentile with a 14-day RSI of 30.4 (OVERSOLD (<32)) and an implied next-earnings move of ±3.9% ($31.55 to $34.11).
Why SMTI Stock slipped -0.26% Today — RQD Quant Desk Flash. Stretched risk/reward at 8x P/E (16% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, SMTI scores 55 out of 100, a D+ grade, with the verdict "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:
Investor implications. Upside drivers in the source data include the 92.7% gross margin, the 36.4% net margin, and the 16.3% ROIC. The trailing P/E of 8.1 and forward P/E of 6.8 suggest a low earnings multiple, but the EV/EBITDA of 29.5 is considerably higher, indicating that enterprise value is elevated relative to EBITDA. Net margin is well above operating margin (7.1%), so reported net income is substantially larger than operating income, and the source data does not explain the difference; a prospective investor should treat the earnings base as requiring verification. The pending MiMedx deal described in the news wire adds a binary event risk that the rating does not model. The RQD verdict reflects these mixed signals.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $103.1M | $7.3M | $37.6M | N/A | $2.2M | $16.6M | $46.0M |
| FY 2024 | $86.7M | $1.3M | $9.7M | N/A | $-0.2M | $15.9M | $30.7M |
| FY 2023 | $65.0M | $-4.2M | $4.3M | N/A | $-3.2M | N/A | N/A |
Revenue grew from $65.0M in FY 2023 to $103.1M in FY 2025, and operating income moved from $-4.2M to $7.3M over the same span. FY 2025 net income of $37.6M is far above operating income of $7.3M, a gap the source data does not explain. Per the Roarable RQD rating, the Altman Z-Score is 3.25 and the Piotroski F-Score is 7/9; ROIC is 16.3% per the market data. Debt rose from $30.7M to $46.0M in FY 2025 and the Debt/Equity ratio is 7.74, indicating high leverage relative to equity.
Per the recent news and catalysts section, the dominant theme is the proposed MiMedx-Sanara merger. Items flagged RED under "RISK WATCH" include a report that the deal faces a fresh regulatory obstacle alongside a note that the stock fell below a key support level for the first time in four months, and a report on the deal spread widening after an FTC second request. YELLOW "MARKET WIRE" items reference FTC clearance as the last major hurdle for a shareholder-approved sale, along with a weekly recap of the second request and the $35 deal price. The source data does not provide the regulatory timeline or the terms of the deal beyond these headlines. The Butterfly supply-chain graph reports no proprietary signals and no links.
Real-time company headlines, analyst actions, and sector developments for Sanara MedTech Inc. (SMTI) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Sanara MedTech Inc. (SMTI) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Sanara MedTech Inc. (SMTI) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Sanara MedTech Inc. (SMTI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Sanara MedTech Inc. (SMTI) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Sanara MedTech Inc. (SMTI) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Sanara MedTech Inc. (SMTI) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Sanara MedTech Inc. (SMTI) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Sanara MedTech Inc. (SMTI) market action, institutional positioning, and fundamental catalysts.
Welcome to the SMTI (Sanara MedTech Inc.) Roar Pit. Current RQD Composite is 55/100 (Roarable Sell — Weak Fundamentals / Trim) in Industrial Specialties. Bulls point to capital efficiency (16.3% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on SMTI, but look at what you are paying: 8.1x trailing P/E with 92.7% gross margins. Unless Sanara MedTech Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on SMTI, the market is fixating on short-term headline noise in Industrial Specialties and ignoring the balance sheet and cash flow trajectory. At $32.92 (52-wk range $16.05 - $35.52), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).